Teleflex downgraded to Market Perform from Outperform at Raymond James

Raymond James downgraded Teleflex (TFX) to Market Perform from Outperform without a price target The firm likes the company’s active portfolio management, but says slowing fundamentals is the “bigger concern.” Urolift stabilization and a pick-up in non-Urolift growth is no longer achievable, and Raymond James now models 2%-3% organic revenue growth with 4%-5% earnings growth over the next two years, the analyst tells investors in a research note. The firm calls the magnitude of Teleflex’s growth slowdown “frustrating.”